Conjunctival melanoma is a rare disease, and little is known about its molecular background. Here, we present the case of a 48-year-old patient with conjunctival melanoma and metachronic lymph node and skin metastasis with KRAS p.K117Y mutation in exon 4 in all the lesions. The cancer genome interpreter predicted this mutation to have driver function. To our knowledge, this is the first time this mutation is found in conjunctival melanoma. An important role in the disease development is suggested.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CMR.0000000000000423 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognosis for patients with metastatic conjunctival melanoma.
Br J Ophthalmol
December 2024
Ophthalmic Plastic Surgery, Department of Plastic Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Metastatic conjunctival melanoma: a multicentre international study.
Br J Ophthalmol
December 2024
Orbit and Oncology, Calle Ophthalmic and Orbit Center, Bogotá, Colombia.
Background: To reveal clinical findings related to metastatic conjunctival melanoma.
Methods: 10 ophthalmic oncology centres (9 countries and 4 continents) shared data to create a large clinical case series. The main outcome measures were the incidence and cumulative risk of systemic metastasis, study mortality rates and Kaplan-Meier patient mortality after developing conjunctival melanoma metastasis.
[TREATMENT UPDATES IN OCULAR ONCOLOGY].
Harefuah
December 2024
Ophthalmology Department, Shaare Tzedek Medical Center.
Malignant tumors of the eye are uncommon, yet of great importance due to their effect on the patient's life and vision. The most common primary intraocular tumors are retinoblastoma in children and uveal melanoma in adults. The most common periocular tumor is basal cell carcinoma in eyelids.
View Article and Find Full Text PDFRate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.
Melanoma Res
December 2024
Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Our primary objective was to estimate the overall response rate to immune checkpoint inhibitors (ICIs) in patients with locally advanced, multiply recurrent, or metastatic conjunctival melanoma treated with ICIs. A retrospective review of all consecutive conjunctival melanoma patients who were treated with ICI between October 2017 and January 2024 was carried out. The study included 16 patients with a median age of 66 years.
View Article and Find Full Text PDFTissue Glue-Assisted Plaque Radiotherapy for Choroidal Tumors with Scleral Thinning.
Retina
November 2024
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Purpose: To evaluate tissue glue-assisted plaque placement regarding accuracy, stability, and longer-term outcomes for choroidal tumors with scleral thinning.
Methods: All patients with tissue glue-assisted plaque radiotherapy at a single ocular oncology center were evaluated for patient demographics, tumor features, surgical details, tumor response, and glue-related complications.
Results: There were 13 patients (mean age 72 years) treated with tissue glue-assisted plaque radiotherapy for choroidal melanoma (n=12) or choroidal metastasis (n=1).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!